View Author
patient study treatment qlq-c score eortc myeloma transplantation eortc qlq-c 30 quality difference symptom hrqol baseline questionnaire hospital cancer qlq-my result netherland subscale scale population cell transplantation follow-up month phase effect diagnosis value mpt arm induction protocol disease future response post-induction trajectory health thalidomide donor disease-speci fic complaints unveri fiable addresses point table re-treatment allogeneic disease-speci ×time auto-sct eortc qlq-my 20 /s floortje mols myeloma patients trial interaction group function dutch characteristic floortje hematol blood inpatient activity reimbursement information randomization allo-sct population-based study transplant registry category complaint melphalan hovon fatigue wiley status medium eindhoven cancer registry